Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 15
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

DNA methylation map of mouse and human brain identifies target genes in Alzheimer’s disease

  • Sanchez-Mut, Jose V.
  • Dierssen Sotos, Mara
  • Esteller, Manel
The central nervous system has a pattern of gene expression that is closely regulated with respect to functional and anatomical regions. DNA methylation is a major regulator of transcriptional activity, and aberrations in the distribution of this epigenetic mark may be involved in many neurological disorders, such as Alzheimer’s disease. Herein, we have analysed 12 distinct mouse brain regions according to their CpG 5’-end gene methylation patterns and observed their unique epigenetic landscapes. The DNA methylomes obtained from the cerebral cortex were used to identify aberrant DNA methylation changes that occurred in two mouse models of Alzheimer’s disease. We were able to translate these findings to patients with Alzheimer’s disease, identifying DNA methylation-associated silencing of three targets genes: thromboxane A2 receptor (TBXA2R), sorbin and SH3 domain containing 3 (SORBS3) and spectrin beta 4 (SPTBN4). These hypermethylation targets indicate that the cyclic AMP response element-binding protein (CREB) activation pathway and the axon initial segment could contribute to the disease., This work was supported by the Human Frontiers Science Program (HFSP) Ref.RGP0018/2007-C, the European Community’s Sixth Framework Programme (FP7/2007-2013) under grant agreement PITN-GA-2009-238242—DISCHROM project and grant agreement 278486-DEVELAGE, NIH Grants NIA P50-AG16573 and HD065160-01, the Instituto de Salud Carlos III—Ministerio de Sanidad y Consumo Proyecto FIS (Fondo Investigación Sanitaria, Spain) through the E-RARE EuroRETT network and CureFXS ERare-EU/FIS PS09102673, Grants P50-AG16573, HD065160-01 and SAF2007-6-8, the Fondation Lejeune (France), the Lilly Foundation (Spain), the Lilly Foundation (Spain), Botin Foundation, and the Cellex Foundation (Catalonia). J.V.S-M is affiliated to the Neuroscience PhD program of the Autonomous University of Barcelona, Spain. ME is an ICREA Reseah Professor.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Mutations in JMJD1C are involved in Rett syndrome and intellectual disability

  • Sáez, Mauricio A.
  • Fernández Rodríguez, Juana
  • Moutinho, Cátia
  • Sanchez-Mut, Jose Vicente
  • Gómez, Antonio
  • Vidal, Enrique
  • Petazzi, Paolo
  • Szczesna, Karolina
  • López Serra, Paula
  • Lucariello, Mario
  • Lorden, Patricia
  • Delgado-Morales, Raul
  • Caridad, Olga J. de la
  • Huertas, Dori
  • Gelpí Buchaca, Josep Lluís
  • Orozco López, Modesto
  • López Dóriga Guerra, Adriana
  • Milà i Recasens, Montserrat
  • Pérez Jurado, Luis A.
  • Pineda, Mercedes
  • Armstrong i Morón, Judith
  • Lázaro García, Conxi
  • Esteller, Manel, 1968-
Purpose: autism spectrum disorders are associated with defects in social response and communication that often occur in the context of intellectual disability. Rett syndrome is one example in which epilepsy, motor impairment, and motor disturbance may co-occur. Mutations in histone demethylases are known to occur in several of these syndromes. Herein, we aimed to identify whether mutations in the candidate histone demethylase JMJD1C (jumonji domain containing 1C) are implicated in these disorders. Methods: we performed the mutational and functional analysis of JMJD1C in 215 cases of autism spectrum disorders, intellectual disability, and Rett syndrome without a known genetic defect. Results: we found seven JMJD1C variants that were not present in any control sample (~ 6,000) and caused an amino acid change involving a different functional group. From these, two de novo JMJD1C germline mutations were identified in a case of Rett syndrome and in a patient with intellectual disability. The functional study of the JMJD1C mutant Rett syndrome patient demonstrated that the altered protein had abnormal subcellular localization, diminished activity to demethylate the DNA damage-response protein MDC1, and reduced binding to MECP2. We confirmed that JMJD1C protein is widely expressed in brain regions and that its depletion compromises dendritic activity. Conclusions: our findings indicate that mutations in JMJD1C contribute to the development of Rett syndrome and intellectual disability.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Generation and Characterization of Rat and Mouse Monoclonal Antibodies Specific for MeCP2 and Their Use in X-Inactivation Studies

  • Jost, K. Laurence
  • Rottach, Andrea
  • Milden, Manuela
  • Bertulat, Bianca
  • Becker, Annette
  • Wolf, Patricia
  • Sandoval, Juan
  • Petazzi, Paolo
  • Huertas, Dori
  • Esteller, Manel, 1968-
  • Kremmer, Elisabeth
  • Leonhardt, Heinrich
  • Cardoso, M. Cristina
Methyl CpG binding protein 2 (MeCP2) binds DNA, and has a preference for methylated CpGs and, hence, in cells, it accumulates in heterochromatin. Even though it is expressed ubiquitously MeCP2 is particularly important during neuronal maturation. This is underscored by the fact that in Rett syndrome, a neurological disease, 80% of patients carry a mutation in the MECP2 gene. Since the MECP2 gene lies on the X chromosome and is subjected to X chromosome inactivation, affected patients are usually chimeric for wild type and mutant MeCP2. Here, we present the generation and characterization of the first rat monoclonal MeCP2 specific antibodies as well as mouse monoclonal antibodies and a rabbit polyclonal antibody. We demonstrate that our antibodies are suitable for immunoblotting, (chromatin) immunoprecipitation and immunofluorescence of endogenous and ectopically expressed MeCP2. Epitope mapping revealed that most of the MeCP2 monoclonal antibodies recognize the C-terminal domain and one the N-terminal domain of MeCP2. Using slot blot analysis, we determined a high sensitivity of all antibodies, detecting amounts as low as 1 ng of MeCP2 protein. Moreover, the antibodies recognize MeCP2 from different species, including human, mouse, rat and pig. Lastly, we have validated their use by analyzing and quantifying X chromosome inactivation skewing using brain tissue of MeCP2 heterozygous null female mice. The new MeCP2 specific monoclonal antibodies described here perform well in a large variety of immunological applications making them a very valuable set of tools for studies of MeCP2 pathophysiology in situ and in vitro.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Whole exome sequencing of Rett syndrome-like patients reveals the mutational diversity of the clinical phenotype

  • Lucariello, Mario
  • Vidal, Enrique
  • Vidal, Silvia
  • Sáez, Mauricio A.
  • Roa, Laura
  • Huertas, Dori
  • Pineda Marfà, Mercè
  • Dalfó Capella, Esther
  • Dopazo, Joaquín
  • Jurado, Paola
  • Armstrong i Morón, Judith
  • Esteller, Manel, 1968-
Classical Rett syndrome (RTT) is a neurodevelopmental disorder where most of cases carry MECP2 mutations. Atypical RTT variants involve mutations in CDKL5 and FOXG1. However, a subset of RTT patients remains that do not carry any mutation in the described genes. Whole exome sequencing was carried out in a cohort of 21 female probands with clinical features overlapping with those of RTT, but without mutations in the customarily studied genes. Candidates were functionally validated by assessing the appearance of a neurological phenotype in Caenorhabditis elegans upon disruption of the corresponding ortholog gene. We detected pathogenic variants that accounted for the RTT-like phenotype in 14 (66.6 %) patients. Five patients were carriers of mutations in genes already known to be associated with other syndromic neurodevelopmental disorders. We determined that the other patients harbored mutations in genes that have not previously been linked to RTT or other neurodevelopmental syndromes, such as the ankyrin repeat containing protein ANKRD31 or the neuronal acetylcholine receptor subunit alpha-5 (CHRNA5). Furthermore, worm assays demonstrated that mutations in the studied candidate genes caused locomotion defects. Our findings indicate that mutations in a variety of genes contribute to the development of RTT-like phenotypes.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Human DNA methylomes of neurodegenerative diseases show common epigenomic patterns

  • Sanchez-Mut, Jose Vicente
  • Heyn, Holger
  • Vidal, Enrique
  • Moran, Sebastian
  • Sayols, Sergi
  • Delgado-Morales, Raul
  • Schultz, Matthew D.
  • Ansoleaga, Belén
  • Garcia Esparcia, Paula
  • Pons-Espinal, Meritxell
  • Lagran, M. M. de
  • Dopazo, Joaquín
  • Rabano, Alberto
  • Avila, Jesús
  • Dierssen, Mara
  • Lott, I.
  • Ferrer, Isidro (Ferrer Abizanda)
  • Ecker, Joseph R.
  • Esteller, Manel, 1968-
Different neurodegenerative disorders often show similar lesions, such as the presence of amyloid plaques, TAU-neurotangles and synuclein inclusions. The genetically inherited forms are rare, so we wondered whether shared epigenetic aberrations, such as those affecting DNA methylation, might also exist. The studied samples were gray matter samples from the prefrontal cortex of control and neurodegenerative disease-associated cases. We performed the DNA methylation analyses of Alzheimer's disease, dementia with Lewy bodies, Parkinson's disease and Alzheimer-like neurodegenerative profile associated with Down's syndrome samples. The DNA methylation landscapes obtained show that neurodegenerative diseases share similar aberrant CpG methylation shifts targeting a defined gene set. Our findings suggest that neurodegenerative disorders might have similar pathogenetic mechanisms that subsequently evolve into different clinical entities. The identified aberrant DNA methylation changes can be used as biomarkers of the disorders and as potential new targets for the development of new therapies.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Circadian cycle-dependent MeCP2 and brain chromatin changes

  • Martínez de Paz, Alexia
  • Vicente Sanchez Mut, Jose
  • Samitier Martí, Mireia
  • Petazzi, Paolo
  • Sáez, Mauricio
  • Szczesna, Karolina
  • Huertas, Dori
  • Esteller, Manel, 1968-
  • Ausió, Juan
Abstract Methyl CpG binding protein 2 (MeCP2) is a chromosomal protein of the brain, very abundant especially in neurons, where it plays an important role in the regulation of gene expression. Hence it has the potential to be affected by the mammalian circadian cycle. We performed expression analyses of mice brain frontal cortices obtained at different time points and we found that the levels of MeCP2 are altered circadianly, affecting overall organization of brain chromatin and resulting in a circadian-dependent regulation of well-stablished MeCP2 target genes. Furthermore, this data suggests that alterations of MeCP2 can be responsible for the sleeping disorders arising from pathological stages, such as in autism and Rett syndrome.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

NuRD-dependent DNA methylation prevents ES cells from accessing a trophectoderm fate

  • Latos, Paulina A.
  • Helliwell, Christine
  • Mosaku, Olukunbi
  • Dudzinska, Dominika A.
  • Stubbs, Bryony
  • Berdasco, María
  • Esteller, Manel, 1968-
  • Hendrich, Brian
Embryonic Stem (ES) cells are able to give rise to the three germ layers of the embryo but are prevented from contributing to the trophoblast. The molecular nature of this barrier between embryonic and trophectodermal cell fates is not clear, but is known to involve DNA methylation. Here we demonstrate that the Nucleosome Remodeling and Deacetylation (NuRD) co-repressor complex maintains the developmental barrier between embryonic and trophectodermal cell fates by maintaining transcriptional silencing of trophectoderm determinant genes in ES cells. We further show that NuRD activity facilitates DNA methylation of several of its target promoters, where it acts non-redundantly with DNA methylation to enforce transcriptional silencing. NuRD-deficient ES cells fail to completely silence expression of the trophectoderm determinant genes Elf5 and Eomes, but this alone is not sufficient to induce transdifferentiation towards the trophectoderm fate. Rather this leaves ES cells capable of activating expression of trophectoderm-specific genes in response to appropriate extracellular signals, enabling them to commit to a trophectodermal cell fate. Our findings clarify the molecular nature of the developmental barrier between the embryonic and trophoblast cell fates, and establish a role for NuRD activity in specifying sites for de novo DNA methylation. (C) 2012. Published by The Company of Biologists Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial Share Alike License (http://creativecommons.org/licenses/by-nc-sa/3.0).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Disrupted microRNA expression caused by Mecp2 loss in a mouse model of Rett syndrome

  • Urdinguio, Rocío G.
  • Fernández, Agustín F.
  • López-Nieva, Pilar
  • Rossi, Simona
  • Huertas, Dori
  • Kulis, Marta
  • Liu, Chang-Gong
  • Croce, Carlo M.
  • Calin, George A.
  • Esteller, Manel
MicroRNAs (miRNAs) are short non-coding RNA molecules that regulate post-transcriptional gene expression. They influence a wide range of physiological functions, including neuronal processes, and are regulated by various mechanisms, such as DNA methylation. This epigenetic mark is recognized by transcriptional regulators such as the methyl CpG binding protein Mecp2. Rett syndrome is a complex neurological disorder that has been associated with mutations in the gene coding for Mecp2. Thus, we examined the possible miRNA misregulation caused by Mecp2 absence in a mouse model of Rett syndrome. Using miRNA expression microarrays, we observed that the brain of Rett syndrome mice undergoes a disruption of the expression profiles of miRNAs. Among the significantly altered miRNAs (26%, 65 of 245), overall downregulation of these transcripts was the most common feature (71%), whilst the remaining 30% were upregulated. Further validation by quantitative RT-PCR demonstrated that the most commonly disrupted miRNAs were miR-146a, miR-146b, miR-130, miR-122a, miR-342 and miR-409 (downregulated), and miR-29b, miR329, miR-199b, miR-382, miR-296, miR-221 and miR-92 (upregulated). Most importantly, transfection of miR-146a in a neuroblastoma cell line caused the downregulation of IL-1 receptor-associated kinase 1 (Irak1) levels, suggesting that the identified defect of miR-146a in Rett syndrome mice brains might be responsible for the observed upregulation of Irak1 in this model of the human disease. Overall, we provide another level of molecular deregulation occurring in Rett syndrome that might be useful for understanding the disease and for designing targeted therapies., We are grateful to the Catalan and Valencian Rett Syndrome Associations for their support. R.G.U. is funded by the Comunidad de Madrid FPI Programme. The research leading to these results has received funding from the European Community's Sixth Framework Programme (FP7/2007-2013) under grant agreement n° PITN-GA-2009-238242—DISCHROM project, from the Instituto de Salud Carlos III—Ministerio de Sanidad y Consumo Proyecto FIS (Fondo Investigación Sanitaria, Spain) through the E-RARE EuroRETT network, from the Fondation Lejeune (France) and from Grant SAF2007-6-8., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Whole exome sequencing of Rett syndrome-like patients reveals the mutational diversity of the clinical phenotype

  • Lucariello, Mario
  • Vidal, Enrique
  • Vidal, Silvia
  • Sáez, Mauricio A.
  • Roa, Laura
  • Huertas, Dori
  • Pineda Marfà, Mercè
  • Dalfó Capella, Esther
  • Dopazo, Joaquín
  • Jurado, Paola
  • Armstrong i Morón, Judith
  • Esteller, Manel
Classical Rett syndrome (RTT) is a neurodevelopmental disorder where most of cases carry MECP2 mutations. Atypical RTT variants involve mutations in CDKL5 and FOXG1. However, a subset of RTT patients remains that do not carry any mutation in the described genes. Whole exome sequencing was carried out in a cohort of 21 female probands with clinical features overlapping with those of RTT, but without mutations in the customarily studied genes. Candidates were functionally validated by assessing the appearance of a neurological phenotype in Caenorhabditis elegans upon disruption of the corresponding ortholog gene. We detected pathogenic variants that accounted for the RTT-like phenotype in 14 (66.6 %) patients. Five patients were carriers of mutations in genes already known to be associated with other syndromic neurodevelopmental disorders. We determined that the other patients harbored mutations in genes that have not previously been linked to RTT or other neurodevelopmental syndromes, such as the ankyrin repeat containing protein ANKRD31 or the neuronal acetylcholine receptor subunit alpha-5 (CHRNA5). Furthermore, worm assays demonstrated that mutations in the studied candidate genes caused locomotion defects. Our findings indicate that mutations in a variety of genes contribute to the development of RTT-like phenotypes.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

DNA methylation map of mouse and human brain identifies target genes in Alzheimer’s disease

  • Sanchez-Mut, Jose V.
  • Dierssen Sotos, Mara
  • Esteller, Manel
The central nervous system has a pattern of gene expression that is closely regulated with respect to functional and anatomical regions. DNA methylation is a major regulator of transcriptional activity, and aberrations in the distribution of this epigenetic mark may be involved in many neurological disorders, such as Alzheimer’s disease. Herein, we have analysed 12 distinct mouse brain regions according to their CpG 5’-end gene methylation patterns and observed their unique epigenetic landscapes. The DNA methylomes obtained from the cerebral cortex were used to identify aberrant DNA methylation changes that occurred in two mouse models of Alzheimer’s disease. We were able to translate these findings to patients with Alzheimer’s disease, identifying DNA methylation-associated silencing of three targets genes: thromboxane A2 receptor (TBXA2R), sorbin and SH3 domain containing 3 (SORBS3) and spectrin beta 4 (SPTBN4). These hypermethylation targets indicate that the cyclic AMP response element-binding protein (CREB) activation pathway and the axon initial segment could contribute to the disease., This work was supported by the Human Frontiers Science Program (HFSP) Ref.RGP0018/2007-C, the European Community’s Sixth Framework Programme (FP7/2007-2013) under grant agreement PITN-GA-2009-238242—DISCHROM project and grant agreement 278486-DEVELAGE, NIH Grants NIA P50-AG16573 and HD065160-01, the Instituto de Salud Carlos III—Ministerio de Sanidad y Consumo Proyecto FIS (Fondo Investigación Sanitaria, Spain) through the E-RARE EuroRETT network and CureFXS ERare-EU/FIS PS09102673, Grants P50-AG16573, HD065160-01 and SAF2007-6-8, the Fondation Lejeune (France), the Lilly Foundation (Spain), the Lilly Foundation (Spain), Botin Foundation, and the Cellex Foundation (Catalonia). J.V.S-M is affiliated to the Neuroscience PhD program of the Autonomous University of Barcelona, Spain. ME is an ICREA Reseah Professor.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Circadian cycle-dependent MeCP2 and brain chromatin changes

  • Martínez de Paz, Alexia
  • Vicente Sanchez Mut, Jose
  • Samitier Martí, Mireia
  • Petazzi, Paolo
  • Sáez, Mauricio
  • Szczesna, Karolina
  • Huertas, Dori
  • Esteller, Manel
  • Ausió, Juan
Abstract Methyl CpG binding protein 2 (MeCP2) is a chromosomal protein of the brain, very abundant especially in neurons, where it plays an important role in the regulation of gene expression. Hence it has the potential to be affected by the mammalian circadian cycle. We performed expression analyses of mice brain frontal cortices obtained at different time points and we found that the levels of MeCP2 are altered circadianly, affecting overall organization of brain chromatin and resulting in a circadian-dependent regulation of well-stablished MeCP2 target genes. Furthermore, this data suggests that alterations of MeCP2 can be responsible for the sleeping disorders arising from pathological stages, such as in autism and Rett syndrome.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Generation and Characterization of Rat and Mouse Monoclonal Antibodies Specific for MeCP2 and Their Use in X-Inactivation Studies

  • Jost, K. Laurence
  • Rottach, Andrea
  • Milden, Manuela
  • Bertulat, Bianca
  • Becker, Annette
  • Wolf, Patricia
  • Sandoval, Juan
  • Petazzi, Paolo
  • Huertas, Dori
  • Esteller, Manel
  • Kremmer, Elisabeth
  • Leonhardt, Heinrich
  • Cardoso, M. Cristina
Methyl CpG binding protein 2 (MeCP2) binds DNA, and has a preference for methylated CpGs and, hence, in cells, it accumulates in heterochromatin. Even though it is expressed ubiquitously MeCP2 is particularly important during neuronal maturation. This is underscored by the fact that in Rett syndrome, a neurological disease, 80% of patients carry a mutation in the MECP2 gene. Since the MECP2 gene lies on the X chromosome and is subjected to X chromosome inactivation, affected patients are usually chimeric for wild type and mutant MeCP2. Here, we present the generation and characterization of the first rat monoclonal MeCP2 specific antibodies as well as mouse monoclonal antibodies and a rabbit polyclonal antibody. We demonstrate that our antibodies are suitable for immunoblotting, (chromatin) immunoprecipitation and immunofluorescence of endogenous and ectopically expressed MeCP2. Epitope mapping revealed that most of the MeCP2 monoclonal antibodies recognize the C-terminal domain and one the N-terminal domain of MeCP2. Using slot blot analysis, we determined a high sensitivity of all antibodies, detecting amounts as low as 1 ng of MeCP2 protein. Moreover, the antibodies recognize MeCP2 from different species, including human, mouse, rat and pig. Lastly, we have validated their use by analyzing and quantifying X chromosome inactivation skewing using brain tissue of MeCP2 heterozygous null female mice. The new MeCP2 specific monoclonal antibodies described here perform well in a large variety of immunological applications making them a very valuable set of tools for studies of MeCP2 pathophysiology in situ and in vitro.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Human DNA methylomes of neurodegenerative diseases show common epigenomic patterns

  • Sanchez-Mut, Jose Vicente
  • Heyn, Holger
  • Vidal, Enrique
  • Moran, Sebastian
  • Sayols, Sergi
  • Delgado-Morales, Raul
  • Schultz, Matthew D.
  • Ansoleaga, Belén
  • Garcia Esparcia, Paula
  • Pons-Espinal, Meritxell
  • Lagran, M. M. de
  • Dopazo, Joaquín
  • Rabano, Alberto
  • Avila, Jesús
  • Dierssen, Mara
  • Lott, I.
  • Ferrer, Isidro (Ferrer Abizanda)
  • Ecker, Joseph R.
  • Esteller, Manel
Different neurodegenerative disorders often show similar lesions, such as the presence of amyloid plaques, TAU-neurotangles and synuclein inclusions. The genetically inherited forms are rare, so we wondered whether shared epigenetic aberrations, such as those affecting DNA methylation, might also exist. The studied samples were gray matter samples from the prefrontal cortex of control and neurodegenerative disease-associated cases. We performed the DNA methylation analyses of Alzheimer's disease, dementia with Lewy bodies, Parkinson's disease and Alzheimer-like neurodegenerative profile associated with Down's syndrome samples. The DNA methylation landscapes obtained show that neurodegenerative diseases share similar aberrant CpG methylation shifts targeting a defined gene set. Our findings suggest that neurodegenerative disorders might have similar pathogenetic mechanisms that subsequently evolve into different clinical entities. The identified aberrant DNA methylation changes can be used as biomarkers of the disorders and as potential new targets for the development of new therapies.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

NuRD-dependent DNA methylation prevents ES cells from accessing a trophectoderm fate

  • Latos, Paulina A.
  • Helliwell, Christine
  • Mosaku, Olukunbi
  • Dudzinska, Dominika A.
  • Stubbs, Bryony
  • Berdasco, María
  • Esteller, Manel
  • Hendrich, Brian
Embryonic Stem (ES) cells are able to give rise to the three germ layers of the embryo but are prevented from contributing to the trophoblast. The molecular nature of this barrier between embryonic and trophectodermal cell fates is not clear, but is known to involve DNA methylation. Here we demonstrate that the Nucleosome Remodeling and Deacetylation (NuRD) co-repressor complex maintains the developmental barrier between embryonic and trophectodermal cell fates by maintaining transcriptional silencing of trophectoderm determinant genes in ES cells. We further show that NuRD activity facilitates DNA methylation of several of its target promoters, where it acts non-redundantly with DNA methylation to enforce transcriptional silencing. NuRD-deficient ES cells fail to completely silence expression of the trophectoderm determinant genes Elf5 and Eomes, but this alone is not sufficient to induce transdifferentiation towards the trophectoderm fate. Rather this leaves ES cells capable of activating expression of trophectoderm-specific genes in response to appropriate extracellular signals, enabling them to commit to a trophectodermal cell fate. Our findings clarify the molecular nature of the developmental barrier between the embryonic and trophoblast cell fates, and establish a role for NuRD activity in specifying sites for de novo DNA methylation. (C) 2012. Published by The Company of Biologists Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial Share Alike License (http://creativecommons.org/licenses/by-nc-sa/3.0).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Mutations in JMJD1C are involved in Rett syndrome and intellectual disability

  • Sáez, Mauricio A.
  • Fernández Rodríguez, Juana
  • Moutinho, Cátia
  • Sanchez-Mut, Jose Vicente
  • Gómez, Antonio
  • Vidal, Enrique
  • Petazzi, Paolo
  • Szczesna, Karolina
  • López Serra, Paula
  • Lucariello, Mario
  • Lorden, Patricia
  • Delgado-Morales, Raul
  • Caridad, Olga J. de la
  • Huertas, Dori
  • Gelpí Buchaca, Josep Lluís
  • Orozco López, Modesto
  • López Dóriga Guerra, Adriana
  • Milà i Recasens, Montserrat
  • Pérez Jurado, Luis A.
  • Pineda, Mercedes
  • Armstrong i Morón, Judith
  • Lázaro García, Conxi
  • Esteller, Manel
Purpose: autism spectrum disorders are associated with defects in social response and communication that often occur in the context of intellectual disability. Rett syndrome is one example in which epilepsy, motor impairment, and motor disturbance may co-occur. Mutations in histone demethylases are known to occur in several of these syndromes. Herein, we aimed to identify whether mutations in the candidate histone demethylase JMJD1C (jumonji domain containing 1C) are implicated in these disorders. Methods: we performed the mutational and functional analysis of JMJD1C in 215 cases of autism spectrum disorders, intellectual disability, and Rett syndrome without a known genetic defect. Results: we found seven JMJD1C variants that were not present in any control sample (~ 6,000) and caused an amino acid change involving a different functional group. From these, two de novo JMJD1C germline mutations were identified in a case of Rett syndrome and in a patient with intellectual disability. The functional study of the JMJD1C mutant Rett syndrome patient demonstrated that the altered protein had abnormal subcellular localization, diminished activity to demethylate the DNA damage-response protein MDC1, and reduced binding to MECP2. We confirmed that JMJD1C protein is widely expressed in brain regions and that its depletion compromises dendritic activity. Conclusions: our findings indicate that mutations in JMJD1C contribute to the development of Rett syndrome and intellectual disability.